The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with Smoldering Myeloma.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
Nivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Respon...
NIVOLUMAB POST TREATMENT WITH IDE-CELPhase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or...
PEMBROLIZUMAB, DECITABINE +/- VENETOCLAXThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
Nivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Respon...
NIVOLUMAB POST TREATMENT WITH IDE-CELThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of myeloma tags that are associated with this tag.
Monoclonal Antibody
Monoclonal antibodies are large, y-shaped, man-made proteins. They are able to target cancer cells by finding and attaching to unique proteins found on the cell's surface.
Programmed Death Receptor-1 (PD-1)
PD-1 is a protein found on the surface of immune cells (called T cells). This protein acts as an "off switch" that may stop your immune system from attacking cancer cells.